--- title: "Organogenesis Holdings IncQ) expected to post a loss of 6 cents a share - Earnings Preview" description: "Organogenesis Holdings IncQ) is anticipated to report a loss of 6 cents per share and a 20.6% decline in quarterly revenue, totaling $103.4 million for the period ending June 30, 2025. This is a decre" type: "news" locale: "en" url: "https://longbridge.com/en/news/251717258.md" published_at: "2025-08-05T22:40:06.000Z" --- # Organogenesis Holdings IncQ) expected to post a loss of 6 cents a share - Earnings Preview > Organogenesis Holdings IncQ) is anticipated to report a loss of 6 cents per share and a 20.6% decline in quarterly revenue, totaling $103.4 million for the period ending June 30, 2025. This is a decrease from $130.23 million a year prior, based on estimates from three analysts. The company's guidance suggested revenue between $100 million and $110 million. The average analyst rating remains "buy," with a 12-month price target of $7.00, reflecting a potential increase of 35.3% from the last closing price of $4.53. - Organogenesis Holdings Inc (ORGO.OQ) (ORGO.O) is expected to show a fall in quarterly revenue when it reports results on August 7 for the period ending June 30 2025 - The Canton Massachusetts-based company is expected to report a 20.6% decrease in revenue to $103.4 million from $130.23 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.The company’s guidance on May 8 2025, for the period ended June 30, was for revenue between $100.00 million and $110.00 million. - ​LSEG’s mean analyst estimate for Organogenesis Holdings Inc is for a loss of 6 cents per share. - The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 3 “strong buy” or “buy,” no “hold” and no “sell” or “strong sell.” - The mean earnings estimate of analysts was unchanged in the last three months. ​ - Wall Street’s median 12-month price target for Organogenesis Holdings Inc is $7.00, about 35.3% above its last closing price of $4.53 Previous quarterly performance (using preferred earnings measure in US dollars). ​ ### QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI ### ENDING ARTESTIMAT ESTIMATE MET, SE % ### E® MISSED Mar. 31 2025 -0.06 -0.06 -0.10 Missed -76.5 Dec. 31 2025 0.00 -0.01 0.06 Beat 580 Sep. 30 2024 -0.02 -0.01 0.09 Beat 700​ Jun. 30 2024 0.00 0.00 0.04 Beat ​​Mar. -0.03 -0.03 -0.02 Beat 25 31 2024 Dec. 31 2023 0.01 0.01 0.00 Missed -100​ Sep. 30 2023 0.00 0.01 0.02 Beat 300 Jun. 30 2023 0.02 0.03 0.04 Beat 60 This summary was machine generated August 5 at 22:40 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) ### Related Stocks - [ORGO.US - Organogenesis](https://longbridge.com/en/quote/ORGO.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Organto Foods veröffentlicht Unternehmenspräsentation über nachhaltige, globale Lieferketten für Bio- und Fairtrade-Lebensmittel | Organto Foods Inc. has released a new corporate presentation showcasing its integrated farm-to-shelf platform for the gl | [Link](https://longbridge.com/en/news/274707505.md) | | Organogenesis Begins FDA Rolling Review for ReNu Biologics License Application | Organogenesis Holdings Inc. has started a rolling submission of a Biologics License Application to the FDA for ReNu®, ai | [Link](https://longbridge.com/en/news/270654458.md) | | Organogenesis' (ORGO) "Buy" Rating Reiterated at BTIG Research | BTIG Research reaffirmed a "buy" rating for Organogenesis (NASDAQ:ORGO) with a target price of $9.00, suggesting a poten | [Link](https://longbridge.com/en/news/270852656.md) | | Organogenesis Director and 10% Owner Glenn H. Nussdorf Reports Sale of Common Shares | Glenn H. Nussdorf, a Director and 10% Owner of Organogenesis Holdings Inc., reported the sale of common shares. The full | [Link](https://longbridge.com/en/news/267594109.md) | | Director and 10% Owner Glenn H. Nussdorf Acquires Common Shares of Organogenesis Holdings Inc | Glenn H. Nussdorf, a Director and 10% Owner of Organogenesis Holdings Inc, has acquired common shares of the company. Th | [Link](https://longbridge.com/en/news/264095000.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.